{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:20:12Z","timestamp":1793319612854,"version":"4.5.0"},"reference-count":35,"publisher":"Society for Neuroscience","issue":"9","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":181,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32GM007367"],"award-info":[{"award-number":["T32GM007367"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HHS | NIH | National Institute on Aging","award":["F30AG084312"],"award-info":[{"award-number":["F30AG084312"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["eNeuro"],"accepted":{"date-parts":[[2024,9,9]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>A new era of disease-modifying therapy for Alzheimer's disease (AD) arrived in 2021 following the Food and Drug Administration's (FDA) decision to grant accelerated approval for aducanumab, an anti-\u03b2-amyloid (A\u03b2) monoclonal antibody designed to target A\u03b2 aggregates, a biological component of AD. More recently, trial outcomes for lecanemab and donanemab, two additional antibodies of this drug class, have shown favorable and significant slowing of metrics for cognitive and functional decline. Lecanemab and donanemab have since received similar FDA approval to aducanumab in January 2023 and July 2024, respectively. Given that these therapies are a clearly emerging tool in the repertoire of clinicians treating AD and related dementias, a critical dialogue has been ongoing regarding the potential impacts and place for these therapies. Here, we seek to contextualize this debate by first considering factors involved in theoretically extrapolating current randomized control trial outcomes to estimate meaningful clinical impacts. In the process of this exercise, we outline a generally useful concept termed Summative Treatment-Associated Benefit measuring Long-term Efficacy\/Effectiveness Area as a metric of summative benefits of treatment over the life course of an individual. Second, we consider current real-world factors, such as conditions of FDA approval and other points involved in clinical decision-making that will influence and\/or temper the actual impacts of this drug class.<\/jats:p>","DOI":"10.1523\/eneuro.0088-24.2024","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:55:12Z","timestamp":1727459712000},"page":"ENEURO.0088-24.2024","source":"Crossref","is-referenced-by-count":30,"title":["What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-\u03b2-amyloid Monoclonal Antibodies in Early Alzheimer's Disease"],"prefix":"10.1523","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8696-1958","authenticated-orcid":false,"given":"Michelle","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n156"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.2","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti\u2013\u03b2-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","article-title":"Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease","volume":"14","author":"Assun\u00e7\u00e3o","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207268"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.7","unstructured":"Cavazzoni C (2021). FDA\u2019s decision to approve new treatment for Alzheimer\u2019s disease. FDA. https:\/\/www.fda.gov\/drugs\/our-perspective\/fdas-decision-approve-new-treatment-alzheimers-disease"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer\u2019s disease drug trials: the importance of eligibility criteria","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.10","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.3390\/diagnostics13132254","article-title":"FDG-PET versus amyloid-PET imaging for diagnosis and response evaluation in Alzheimer\u2019s disease: benefits and pitfalls","volume":"13","author":"H\u00f8ilund-Carlsen","year":"2023","journal-title":"Diagnostics"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-publhealth-052120-012811","article-title":"Health-related quality of life measurement in public health","volume":"43","author":"Kaplan","year":"2022","journal-title":"Annu Rev Public Health"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.15","first-page":"9","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer\u2019s disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.16","unstructured":"Lash TL , VanderWeele TJ , Haneause S , Rothman K (2021) Modern epidemiology , Ed. 4. Philadelphia : Wolters Kluwer Health."},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.17","unstructured":"Lin G , Whittington MD , Wright A , Agboola F , Herron-Smith S , Pearson SD (2023) Lecanemab for early Alzheimer\u2019s disease: Final Evidence Report. Instit for Clin and Econ Rev ."},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jama.2023.11704","article-title":"Donanemab for Alzheimer disease\u2014who benefits and who is harmed?","volume":"330","author":"Manly","year":"2023","journal-title":"JAMA"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.20","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.2023.17131","article-title":"Role of registries in Medicare coverage of new Alzheimer disease drugs","volume":"330","author":"Odouard","year":"2023","journal-title":"JAMA"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2023.11703","article-title":"Amyloid-targeting monoclonal antibodies for Alzheimer disease","volume":"330","author":"Rabinovici","year":"2023","journal-title":"JAMA"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207757"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.23","unstructured":"Rising Leqembi Prescriptions Are Straining Clinic Capacity (2024). Alzforum. https:\/\/www.alzforum.org\/news\/research-news\/rising-leqembi-prescriptions-are-straining-clinic-capacity"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jama.2023.11702","article-title":"Novel Alzheimer disease treatments and reconsideration of US pharmaceutical reimbursement policy","volume":"330","author":"Rosenthal","year":"2023","journal-title":"JAMA"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01369-8"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.317"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.31","unstructured":"US Food and Drug Administration (2019). Patient-focused drug development guidance public workshop. incorporating clinical outcome assessments into endpoints for regulatory decision-making. https:\/\/www.fda.gov\/media\/132505\/download"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.32","unstructured":"US Food and Drug Administration (2024). FDA approves treatment for adults with Alzheimer\u2019s disease. FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.34","first-page":"227","article-title":"A combined measure of cognition and function for clinical trials: the integrated Alzheimer\u2019s disease rating scale (iADRS)","volume":"2","author":"Wessels","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"2024092710550479000_11.9.ENEURO.0088-24.2024.35","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12312"}],"container-title":["eneuro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/ENEURO.0088-24.2024","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/ENEURO.0088-24.2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:55:19Z","timestamp":1727459719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eneuro.org\/lookup\/doi\/10.1523\/ENEURO.0088-24.2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,27]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1523\/ENEURO.0088-24.2024"],"URL":"https:\/\/doi.org\/10.1523\/eneuro.0088-24.2024","relation":{},"ISSN":["2373-2822"],"issn-type":[{"value":"2373-2822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}